Prescriber's Corner
Enzalutamide: A New Agent for the Prostate Cancer Treatment Armamentarium
Stephanie B. McCutcheon, PharmD
From Cancer Centers of the Carolinas, a department of the Greenville Hospital System, Greenville, South Carolina
The author has no conflicts of interest to disclose.
Correspondence to: Stephanie B. McCutcheon, PharmD, Cancer Centers of the Carolinas, 65 International Drive, Greenville, SC 29607.
E-mail: smccutcheon@ghs.org
J Adv Pract Oncol 2013;4:182–185 |
DOI: 10.6004/jadpro.2013.4.3.7 |
© 2013 Harborside Press®
ABSTRACT
The development of disease resistance to current drugs underlies the need for additional treatment options in metastatic prostate cancer. Learn the key facts about enzalutamide (Xtandi), recently approved for use in patients with castration-resistant disease who have previously taken docetaxel.
For access to the full length article, please
sign in.
